Skip to main content
IDXX logo

IDXX · Idexx Laboratories Inc · Documents

Track IDXX — free
Market Cap
$55.20B
Shares
78.79M
Volume · Nov 16 491.5K Avg daily vol (3M) 567.85K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $4.3B up 10.4% 10-K filed Feb 20, 2026 Quarterly report FY2026 Q3 Revenue $1.21B up 9.9% 10-Q filed Nov 2, 2026 Latest results Revenue grows 10%, EPS reaches $4.01, guidance rises 8-K filed Nov 2, 2026 Earnings call Q3 2026 earnings call Held Nov 2, 2026
2026
Nov 2
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 9.9% as operating income grows 13.4%

IDEXX reported quarterly revenue of 1,214,237 thousand dollars, up 9.9%, and income from operations of 402,348 thousand dollars, up 13.4%. Organic revenue grew 10.0%, led by higher recurring revenue volumes and realized prices.

Revenue $1.21B ▲ 9.9% Net income $317.15M ▲ 15.5% Diluted EPS $4.01 ▲ 17.9%
Read from the MD&A section
4 source passages
Revenue | 1,214,237 | | 1,105,239 | | 108,998 | 9.9% Income from operations | 402,348 | 33.1% | 354,846 | 32.1% | 47,502 | 13.4% Total Company | 1,214,237 | 1,105,239 | 108,998 | 9.9% | (0.2%) | 0.1% | 10.0% The increase in IDEXX VetLab consumables revenue was primarily due to higher volumes and higher realized prices. Open the document at this passage
Nov 2
Earnings call
Raises 2026 revenue and EPS outlook

IDEX Laboratories reported third-quarter organic revenue growth of 10% and EPS of $4.01, up 18% as reported, and raised its 2026 revenue outlook to $4,741,000,000 to $4,767,000,000 and EPS outlook to $14.96 to $15.16 per share.

5 source passages
Good morning, and welcome to the IDEX Laboratories third quarter 2026 earnings conference call. Revenue increased 10% organically earnings per share of $4.01 in the quarter, an increase of 18% as reported and 22% on a comparable basis. We are raising our full-year revenue range to $4,741,000,000 to $4,767,000,000 We also increased our full-year EPS outlook to $14.96 to $15.16 per share Open the document at this passage
Nov 2
Current report 8-K
Revenue grows 10%, EPS reaches $4.01, guidance rises

IDEXX Laboratories reported third-quarter revenue of $1,214 million, up 10%, and diluted EPS of $4.01, up 18%, as it raised 2026 revenue guidance to $4,741 million - $4,767 million and EPS outlook to $14.96 - $15.16.

Financial results Read from the first part of this long document
4 source passages
The Company reports revenues of $1,214 million for the third quarter of 2026, an increase of 10% as reported and organic, driven by Companion Animal Group ("CAG") growth of 10% as reported and organic. Third quarter earnings per diluted share (“EPS”) were $4.01, an increase of 18% as reported and 22% on a comparable basis. The Company is updating its full year revenue growth guidance range to $4,741 million - $4,767 million, or reported growth of 10.1% - 10.8%, an increase of $32 million at midpoint, including $5 million related to the recent CoVet acquisition. The Company updated its EPS outlook range to $14.96 - $15.16, a $0.25 increase compared to prior guidance midpoint, reflecting 15% reported and 16% comparable growth. Open the document at this passage
Aug 4
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.22B ▲ 9.7% Net income $338.41M ▲ 15.1% Diluted EPS $4.27 ▲ 17.6%
May 5
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $1.14B ▲ 14.3% Net income $278.45M ▲ 14.7% Diluted EPS $3.47 ▲ 17.2%
Feb 20
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $4.3B ▲ 10.4% Net income $1.06B ▲ 19.3% Diluted EPS $13.08 ▲ 22.6%
2025
Nov 3
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $1.11B ▲ 13.3% Net income $274.61M ▲ 17.9% Diluted EPS $3.40 ▲ 21.4%
Aug 4
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $1.11B ▲ 10.6% Net income $293.99M ▲ 44.6% Diluted EPS $3.63 ▲ 48.8%
May 1
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $998.43M ▲ 3.6% Net income $242.68M ▲ 3.0% Diluted EPS $2.96 ▲ 5.3%
Feb 21
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $3.9B ▲ 6.5% Net income $887.87M ▲ 5.1% Diluted EPS $10.67 ▲ 6.1%
2024
Oct 31
Quarterly report 10-Q FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Revenue $975.54M ▲ 6.6% Net income $232.84M ▲ 9.7% Diluted EPS $2.80 ▲ 10.7%
Showing 1–50 of 135 documents
Key facts CIK 874716 CUSIP 45168D104 13F (30d) 1100 filings 1044 filers Visit website Investor relations